Multi-gene assays: are they to become standard adjuvant therapy for ER-positive breast cancer?

    loading  Checking for direct PDF access through Ovid

Abstract

▪ It looks very promising for the use of multi-gene assays in decisions about breast cancer management. Both the 21-gene recurrence score and the 70-gene profiling assay have good data showing that they can be used to guide decisions in both patients with nodenegative and node-positive disease.

Related Topics

    loading  Loading Related Articles